Mark Ragosa - May 1, 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role: CHIEF FINANCIAL OFFICER
Signature: /s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol: KNSA
Transactions as of: May 1, 2025
Transactions value $: $0
Form type: 4
Date filed: 5/5/2025, 04:50 PM
Previous filing: May 1, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Ragosa Mark	CHIEF FINANCIAL OFFICER	23 OLD BOND STREET, THIRD FLOOR, LONDON, UNITED KINGDOM	/s/ Madelyn Zeylikman, Attorney-in-Fact	2025-05-05	0001835458

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNSA	Performance Share Unit	Award	$0	+4.56K		$0.00	4.56K	May 1, 2025	Class A Ordinary Share	4.56K		Direct	F1, F2, F3
transaction	KNSA	Performance Share Unit	Award	$0	+4.79K	+5317.78%	$0.00	4.88K	May 1, 2025	Class A Ordinary Share	4.79K		Direct	F1, F2, F4
transaction	KNSA	Performance Share Option	Award	$0	+7.37K		$0.00	7.37K	May 1, 2025	Class A Ordinary Share	7.37K	$27.74	Direct	F2, F5
transaction	KNSA	Performance Share Option	Award	$0	+7.61K		$0.00	7.61K	May 1, 2025	Class A Ordinary Share	7.61K	$27.74	Direct	F2, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance
F2	The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.
F3	The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.
F4	The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.
F5	The Performance Share Options shall vest and become exercisable, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions.
F6	The Performance Share Options shall vest and become exercisable, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.